Brian S. Henick

This study identifies that 3q-gain aneuploidy in squamous cell carcinomas creates a vulnerability to SREBP-pathway inhibition, offering a target for lipid-targeted therapies.

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

This study identifies molecular and immune features associated with response to anti-PD-(L)1 therapy in NSCLC using a cohort of 393 patients.

This study develops a method for single-cell and whole-genome sequencing of frozen clinical specimens, demonstrating its utility in analyzing tumor evolution and rare disease biospecimens.